Monoclonal antibodies for treating COVID-19
- PMID: 33597176
- DOI: 10.3949/ccjm.88a.ccc074
Monoclonal antibodies for treating COVID-19
Abstract
Bamlanivimab and casirivimab-imdevimab are novel virus-neutralizing monoclonal antibodies authorized to treat mild to moderate COVID-19 in outpatients at risk for progression to severe disease. Treatment early in the disease may show efficacy in reducing progression to severe disease, although safety and efficacy data are limited. They are not authorized for hospitalized patients with more advanced disease.
Copyright © 2021 The Cleveland Clinic Foundation. All Rights Reserved.
LinkOut - more resources
Full Text Sources
Other Literature Sources